Showing 4341-4350 of 5771 results for "".
- Avellino Exceeds 1 Million COVID-19 Tests in 2020 and Welcomes New Executive Team Hires In 2021https://modernod.com/news/avellino-exceeds-1-million-covid-19-tests-in-2020-and-welcomes-new-executive-team-hires-in-2021/2478756/Avellino Lab USA announced that the company performed over 1 million AvellinoCoV2 COVID-19 tests since March 2020, and has further expanded the company’s executive team to drive additional development and commercial growth in 2021. Chief Scientific Officer, Nazneen Aziz, PhD, and Global Head of S
- NTC Grants to Zhaoke Exclusive License and Distribution Rights in Asia for NTC014 for Bacterial Conjunctivitishttps://modernod.com/news/ntc-grants-to-zhaoke-exclusive-license-and-distribution-rights-in-asia-for-ntc014-for-bacterial-conjunctivitis/2478758/Italy-based NTC and Zhaoke (Hong Kong) Ophthalmology Pharmaceuticals Limited announced an agreement for exclusive license and distribution rights of NTC014 fixed combination of a quinolone antibiotic and a NSAID in eye drops. Zhaoke will market NTC014 in
- Glaukos’ iDose TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Studyhttps://modernod.com/news/glaukos-idose-tr-demonstrates-sustained-iop-reduction-and-favorable-safety-profile-over-24-months-in-phase-2b-study/2478753/Glaukos announced that its iDose TR sustained-release travoprost implant continued to provide sustained substantial reductions in IOP in a 24-month interim analysis of the ongoing 36-month phase 2b clinical trial conducted under a U.S. investigational new drug (IND) protocol. Administered
- US IDE Trial Results for Glaukos’ iStent infinite Show Reduction in IOPhttps://modernod.com/news/us-ide-trial-results-for-glaukos-istent-infinite-show-reduction-in-iop/2478754/Glaukos announced that 12-month U.S. Investigational Device Exemption (IDE) pivotal trial data showed that its iStent infinite Trabecular Micro-Bypass System achieved a substantial reduction in mean diurnal IOP in patients with open-angle glaucoma uncontrolled by prior surgical or medical therapy
- Pacific Vision Surgery Center Opens Doors to Bay Area Communityhttps://modernod.com/news/pacific-vision-surgery-center-opens-doors-to-bay-area-community/2478751/Pacific Vision Foundation has announced the opening of the new Pacific Vision Surgery Center. This state-of-the-art surgical facility is the manifestation of Pacific Vision Foundation’s mission to make excellent eye care available for all, regardless of ability to pay, while training the next gen
- EMA Receives Conditional Marketing Request for AstraZeneca’s COVID-19 Vaccinehttps://modernod.com/news/ema-receives-conditional-marketing-request-for-astrazenecas-covid-19-vaccine/2478752/The European Medicines Agency announced Tuesday that it received an application for conditional marketing authorization of AstraZeneca and the University of Oxford’s COVID-19 vaccine AZD1222. The regulator noted that the vaccine will be reviewed under an accelerated timeline with an opinion
- Johnson & Johnson Vision Releases New Guide to Help Slow the Progression of Myopia in Childrenhttps://modernod.com/news/johnson-johnson-vision-releases-new-guide-to-help-slow-the-progression-of-myopia-in-children/2478750/Johnson & Johnson Vision announced a new guide with recommendations for eye care professionals to assess, monitor and treat myopia in children. The guide, titled “Managing Myopia: A Clinical Response to the Growing Epidemic,” is a result of a year of collaboration with lead
- Notal Vision Launches First US Home OCT Longitudinal Study with Patient Self-Operated Devicehttps://modernod.com/news/notal-vision-launches-first-us-home-oct-longitudinal-study-with-patient-self-operated-device/2478748/Notal Vision announced that it has initiated the first US-based study using its investigational home-based optical coherence tomography (OCT) platform. The study will evaluate the ability of subjects with wet age-rela
- Turn Biotechnologies Licenses Technology that Aims to Unwind the Effects of Aging at a Cellular Levelhttps://modernod.com/news/turn-biotechnologies-licenses-technology-that-aims-to-unwind-the-effects-of-aging-at-a-cellular-level/2478747/Turn Biotechnologies announced that it has acquired the global rights for new technology that aims to reprogram cells to undo many of the effects of aging. The company licensed its epigenetic reprogramming of age (ERA) technology from Stanford University, where
- EyeSouth Partners Expands Network to Include 28 Doctors in Ohio and Kentucky Through Affiliation with Midwest Eye Centerhttps://modernod.com/news/eyesouth-partners-expands-network-to-include-28-doctors-in-ohio-and-kentucky-through-affiliation-with-midwest-eye-center/2478742/EyeSouth Partners has announced that it has completed an affiliation with Midwest Eye Center (MWEC), representing EyeSouth’s first in the states of Ohio and Kentucky. Terms of the deal were not disclosed. Midwest Eye Center is led by Drs. Mark Cepela, Jean Noll, Faiz Khaja, Saif Jaw